Track Altamira Therapeutics's long-term debt ($240K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2024), CYTO shows a long-term debt of $240K. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CYTO's long-term debt is now $240K (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Altamira Therapeutics is outperforming or lagging.
Tracking CYTO's long-term debt over time shows whether Altamira Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $240K In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Altamira Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $240K) with ownership activity and broader fundamentals.
Altamira Therapeutics's long-term debt is $240K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.